Dr. Cheng Huang 黄成
Chief Physician, Associate Professor
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and minimally invasive treatment of benign and malignant liver tumors, including metastatic liver cancer. Management of gallbladder and hilar cholangiocarcinoma, prevention of postoperative recurrence, liver transplantation, and conversion therapy for advanced hepatocellular carcinoma.
Dr. Huang holds an MD and completed a postdoctoral fellowship at the National Cancer Center Japan. Since 1997, Dr. Huang has performed approximately 6,000 liver resections and over 1,000 liver transplants. Research focuses on clinical diagnosis and basic science of liver cancer. Dr. Huang has published over 60 papers and serves as a reviewer for multiple journals.
Professional roles
- Standing Committee Member, Liver Microcirculation Professional Committee, Chinese Society of Microcirculation
- Standing Committee Member, Tumor Surgery Branch, Minimally Invasive Therapy Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Tumor Immunotherapy Society, China Medical Promotion Association
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Huang Cheng). Papers usually list the name as Cheng Huang or Huang C.
Selected publications
96 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Liver Cancer, 2026 (senior author): Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma. PubMed 41815110
- Nat Commun, 2025 (senior author): Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma. PubMed 41387425
- Adv Sci (Weinh), 2025 (senior author): CXCL6 Reshapes Lipid Metabolism and Induces Neutrophil Extracellular Trap Formation in Cholangiocarcinoma Progression and Immunotherapy Resistance. PubMed 40305734
- Liver Cancer, 2025 (senior author): Depth of Radiographic Response as an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy following Targeted Therapy plus Immunotherapy. PubMed 40255871
- BMC Cancer, 2023 (first author): Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study. PubMed 37158833
- Front Immunol, 2022 (senior author): Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody. PubMed 36505445
- Cancer Commun (Lond), 2022 (first author): Peripheral naïve CD8(+) T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a biomarker study. PubMed 35994567
- Carcinogenesis, 2021 (senior author): CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression. PubMed 34314478
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion